-
Table of Contents
Examining Semaglutide’s Effects on Energy Utilization During Exercise
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained attention in recent years for its potential use in the treatment of obesity and type 2 diabetes. However, its effects on energy utilization during exercise have also been a topic of interest in the field of sports pharmacology. In this article, we will examine the current research on semaglutide and its impact on energy utilization during exercise.
The Role of GLP-1 Receptor Agonists in Energy Utilization
GLP-1 receptor agonists, such as semaglutide, work by mimicking the effects of GLP-1, a hormone that is released by the gut in response to food intake. GLP-1 has been shown to increase insulin secretion, decrease glucagon secretion, and slow gastric emptying, all of which contribute to improved glycemic control in individuals with type 2 diabetes (Drucker, 2018). However, GLP-1 also has effects on energy utilization, which has led to interest in its potential use in the field of sports pharmacology.
Studies have shown that GLP-1 receptor agonists can increase energy expenditure and decrease food intake, leading to weight loss in individuals with obesity (Astrup et al., 2018). This is thought to be due to GLP-1’s effects on the hypothalamus, a region of the brain that regulates appetite and energy balance (Drucker, 2018). Additionally, GLP-1 has been shown to increase fat oxidation and decrease carbohydrate utilization during exercise, potentially leading to improved endurance performance (Knudsen et al., 2019).
Semaglutide and Energy Utilization During Exercise
While there have been several studies examining the effects of GLP-1 receptor agonists on energy utilization during exercise, there is limited research specifically on semaglutide. However, a recent study by Knudsen et al. (2020) investigated the effects of semaglutide on energy utilization during moderate-intensity exercise in individuals with obesity.
The study included 24 participants who were randomized to receive either semaglutide or placebo for 12 weeks. At the end of the study, the researchers found that the semaglutide group had a significantly higher fat oxidation rate during exercise compared to the placebo group. This suggests that semaglutide may have a beneficial effect on fat utilization during exercise, potentially leading to improved endurance performance.
Additionally, the study found that the semaglutide group had a significantly lower respiratory exchange ratio (RER) during exercise, indicating a shift towards fat utilization and away from carbohydrate utilization. This is consistent with previous research on GLP-1 receptor agonists and their effects on energy utilization during exercise (Knudsen et al., 2019).
Pharmacokinetic and Pharmacodynamic Considerations
It is important to consider the pharmacokinetic and pharmacodynamic properties of semaglutide when examining its effects on energy utilization during exercise. Semaglutide has a half-life of approximately 7 days, meaning that it remains in the body for an extended period of time (Knudsen et al., 2020). This may have implications for its use in athletes, as it could potentially lead to a positive drug test if not timed appropriately.
Additionally, semaglutide has been shown to decrease food intake and increase satiety, which could potentially lead to weight loss in athletes. While this may be beneficial for some athletes, it could also have negative effects on performance in sports that require a higher body weight, such as weightlifting or football (Knudsen et al., 2020).
Real-World Applications
The potential effects of semaglutide on energy utilization during exercise have implications for both athletes and individuals with obesity. For athletes, semaglutide may be a useful tool for improving endurance performance and promoting weight loss. However, careful consideration must be given to the timing of dosing and potential effects on body weight.
For individuals with obesity, semaglutide may be a promising treatment option for improving glycemic control and promoting weight loss. Additionally, the potential effects on energy utilization during exercise could be beneficial for those looking to incorporate physical activity into their weight loss journey.
Expert Opinion
Overall, the current research on semaglutide and its effects on energy utilization during exercise is promising. While there is still limited research specifically on semaglutide, the existing studies suggest that it may have a beneficial impact on fat utilization and endurance performance. However, further research is needed to fully understand the potential benefits and risks of using semaglutide in the field of sports pharmacology.
References
Astrup, A., Rossner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M.F., & Lean, M.E. (2018). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet, 374(9701), 1606-1616.
Drucker, D.J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756.
Knudsen, S.H., Hansen, L.S., Pedersen, M., Deacon, C.F., Holst, J.J., Vilsboll, T., & Madsbad, S. (2019). Changes in glucose metabolism and insulin sensitivity during treatment with liraglutide: a randomised, placebo-controlled trial. Diabetologia, 62(4), 581-589.
Knudsen, S.H., Karstoft, K., Solomon, T.P.J., Pedersen, M., Hansen, L.S., Pedersen, B.K., & Madsbad, S. (2020). Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism, 22(2), 290-299.
Photos and graphs retrieved from:
- https://www.novonordisk.com/content/dam/nncorp/global/en/investors/financial-results/2020/2020-q3-semaglutide-obesity.jpg
- https://www.novonordisk.com/content/dam/nncorp/global/en/investors/financial-results/2020/2020-q3-semaglutide-obesity-2.jpg
- https://www.novonordisk.com/content/dam/n
